BCLI
Price
$2.24
Change
+$0.45 (+25.14%)
Updated
Dec 18, 04:59 PM (EDT)
EYPT
Price
$7.44
Change
-$0.58 (-7.23%)
Updated
Dec 18, 04:59 PM (EDT)
70 days until earnings call
Ad is loading...

BCLI vs EYPT

Header iconBCLI vs EYPT Comparison
Open Charts BCLI vs EYPTBanner chart's image
Brainstorm Cell Therapeutics
Price$2.24
Change+$0.45 (+25.14%)
Volume$8.28K
CapitalizationN/A
EyePoint Pharmaceuticals
Price$7.44
Change-$0.58 (-7.23%)
Volume$5.28K
CapitalizationN/A
BCLI vs EYPT Comparison Chart
Loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCLI vs. EYPT commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLI is a StrongBuy and EYPT is a StrongBuy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (BCLI: $2.25 vs. EYPT: $7.44)
Brand notoriety: BCLI and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCLI: 424% vs. EYPT: 68%
Market capitalization -- BCLI: $10.21M vs. EYPT: $507.79M
BCLI [@Biotechnology] is valued at $10.21M. EYPT’s [@Biotechnology] market capitalization is $507.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCLI’s FA Score shows that 0 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • BCLI’s FA Score: 0 green, 5 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCLI’s TA Score shows that 6 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • BCLI’s TA Score: 6 bullish, 3 bearish.
  • EYPT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCLI is a better buy in the short-term than EYPT.

Price Growth

BCLI (@Biotechnology) experienced а +40.62% price change this week, while EYPT (@Biotechnology) price change was -9.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

BCLI is expected to report earnings on Nov 14, 2024.

EYPT is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($508M) has a higher market cap than BCLI($10.2M). BCLI YTD gains are higher at: -56.288 vs. EYPT (-65.296). BCLI has higher annual earnings (EBITDA): -13.06M vs. EYPT (-102.3M). EYPT has more cash in the bank: 254M vs. BCLI (168K). BCLI has less debt than EYPT: BCLI (841K) vs EYPT (21.9M). EYPT has higher revenues than BCLI: EYPT (45.7M) vs BCLI (0).
BCLIEYPTBCLI / EYPT
Capitalization10.2M508M2%
EBITDA-13.06M-102.3M13%
Gain YTD-56.288-65.29686%
P/E RatioN/AN/A-
Revenue045.7M-
Total Cash168K254M0%
Total Debt841K21.9M4%
FUNDAMENTALS RATINGS
BCLI vs EYPT: Fundamental Ratings
BCLI
EYPT
OUTLOOK RATING
1..100
2352
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6585
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (63) in the Pharmaceuticals Major industry is in the same range as BCLI (90) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

BCLI's Price Growth Rating (65) in the Computer Peripherals industry is in the same range as EYPT (85) in the Pharmaceuticals Major industry. This means that BCLI’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (21) in the Pharmaceuticals Major industry is significantly better than the same rating for BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew significantly faster than BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCLIEYPT
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSLIX16.73N/A
N/A
Goldman Sachs Large Cap Value Instl
KAUIX6.11-0.05
-0.81%
Federated Hermes Kaufmann IS
AMDWX13.47-0.12
-0.88%
Amana Developing World Investor
SLPSX94.72-1.14
-1.19%
ProFunds Small Cap Svc
PSSJX26.88-0.38
-1.39%
Principal SmallCap S&P 600 Index J

BCLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCLI has been loosely correlated with VBIZF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCLI jumps, then VBIZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
+15.48%
VBIZF - BCLI
35%
Loosely correlated
N/A
ATHE - BCLI
35%
Loosely correlated
-1.73%
BLRX - BCLI
30%
Poorly correlated
-2.34%
EYPT - BCLI
28%
Poorly correlated
+5.39%
VERU - BCLI
27%
Poorly correlated
-9.18%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+5.39%
LYRA - EYPT
58%
Loosely correlated
-1.94%
ATHE - EYPT
54%
Loosely correlated
-1.73%
GLYC - EYPT
47%
Loosely correlated
-2.83%
OCUL - EYPT
44%
Loosely correlated
+0.45%
BEAM - EYPT
39%
Loosely correlated
-1.21%
More